MEPI talked about the role of biomarkers in personalised treatment of cancer
Personalized and precision medicine (APM) is becoming the main direction of development of medical science and practice. Its main task is to determine which drugs will be effective for the patient, given its genetic characteristics and individual forms of the disease, and also for his immediate family. Over time, personalized medicine using biomarkers will be a critical part of preventive and curative work of doctors-oncologists and will help to reduce the risk of illness for people from risk groups.